VBI hepatitis B vaccine meets main goals in late-stage trial

VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine against GlaxoSmithKline's Engerix-B met its main goals.

The trial administered VBI's Sci-B-Vac at a 10 microgram dose against a 20 microgram dose of Engerix-B, a vaccine which was first approved in the United States in 1989.